This article was downloaded by:


On: 27 January 2011

Access details: Access Details: Free Access

Publisher *Taylor & Francis* 

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

# 2-Deoxy-D-Ribofuranosylation of Ethyl 5-Aminoimidazole-4-Carboxylate by Biotransformation and Chemical Methods

David Ewing<sup>a</sup>; Robert W. Humble<sup>b</sup>; Antonin Holy<sup>c</sup>; Grahame Mackenzie<sup>b</sup>; Gordon Shaw<sup>d</sup>; Ivan Votruba<sup>c</sup>

<sup>a</sup> University of Hull, Hull, U.K. <sup>b</sup> Humberside College of Higher Education, Hull, U.K. <sup>c</sup> University of Bradford, Bradford, U.K. <sup>d</sup> Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Praha 6, Czechoslovakia

To cite this Article <code>Ewing</code>, <code>David</code> , <code>Humble</code>, <code>Robert W.</code> , <code>Holy</code>, <code>Antonin</code> , <code>Mackenzie</code>, <code>Grahame</code> , <code>Shaw</code>, <code>Gordon and Votruba</code>, <code>Ivan(1989)</code> '2-Deoxy-D-Ribofuranosylation of Ethyl 5-Aminoimidazole-4-Carboxylate by Biotransformation and Chemical Methods', <code>Nucleosides</code>, <code>Nucleotides</code> and <code>Nucleic Acids</code>, 8: 5, <code>1177 — 1178</code>

To link to this Article: DOI: 10.1080/07328318908054323 URL: http://dx.doi.org/10.1080/07328318908054323

#### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## 2-DEOXY-D-RIBOFURANOSYLATION OF ETHYL 5-AMINOIMIDAZOLE-4-CARBOXYLATE BY BIOTRANSFORMATION AND CHEMICAL METHODS

David Ewing<sup>a</sup>, Robert W. Humble<sup>b</sup>, Antonin Holy<sup>c</sup>, Grahame Mackenzie<sup>b</sup>, Gordon Shaw and Ivan Votruba<sup>c</sup>.
University of Hull, Hull, Hu6 7RX, U.K.<sup>a</sup>
Humberside College of Higher Education, Hull, Hu6 7RT, U.K.<sup>b</sup>
University of Bradford, Bradford, BD7 1DP, U.K.
Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, 16610 Praha 6, Czechoslovakia<sup>c</sup>.

In our studies aimed at the synthesis of inhibitors of enzymes involved in the *de novo* biosynthesis of purine nucleotides, the arabinosyl nucleoside (1a), which is analogous to CAIR (1b), a central intermediate in the pathway, showed significant inhibition and substrate activities. We were therefore interested to synthesize the related 2-deoxy-D-ribosyl nucleotide (1c) for further enzymological studies.

Previously reported routes to 2-deoxy-D-ribofuranosyl-aminoimidazole nucleosides have involved either degradation of purine nucleosides  $^2$  or condensation of 2-deoxyribofuranosyl halides with, such as, the nitro imidazole ester (2a) followed by hydrogenation.

We have earlier reported the synthesis of the 1-8-D-arabinofuranosyl-5-aminoimidazole (1e) by direct condensation of the aminoimidazole (2b) with 2,3,5-tri-0-benzyl-a-D-arabinofuranosyl chloride in hot acetonitrile containing triethylamine. Using the same solvent conditions and imidazole (2b) we performed a comparable reaction using the 2-deoxyribofuranosyl halide (3). The reaction mixture revealed two U.V. and Bratton-Marshall<sup>0</sup> (diazotisable) spots on silica gel T.L.C. (ethyl acetate-toluene 1:1). Two fractions (A) and (B) were obtained from column chromatography (silica gel using ethyl acetate-toluene 3:7) of the reaction mixture, which corresponded to the two T.L.C. spots. Fraction (A) was found by NMR spectroscopy to contain the following isomeric mixture of nucleosides (20% base conversion) 55% α-N<sup>1</sup>(4). 19% B-N¹(1d), 19%  $\alpha$ -N³ (5) and 7% B-N³(6a). The components found to constitute fraction (B) (34% base conversion) were 77%  $\alpha$ -N³(5) and 23%  $\beta-N^3$  (6a). The reaction was repeated in the absence of triethylamine. Two fractions (C) and (D) were again separated using the same chromatographic conditions but different isomeric ratios were obtained: fraction (C) (15% base conversion) contained 10%  $\alpha$ -N<sup>1</sup>(4) and 90%  $\beta$ -N<sup>1</sup>(1d) whereas fraction (D) (35% base conversion) contained  $80\% \text{ }\alpha-\text{N}^3(5)$  and  $20\% \ \beta-N^{3}(6a)$ .

In light of the difficulties encountered in obtaining pure isomers of 2-deoxy- $\beta$ -D-ribofuranosyl-5-aminoimidazole nucleosides, by chemical synthesis, an alternative route was investigated which involved biotransformation on encapsulated cells; a technique previously reported by Holy and Votruba<sup>7</sup>. The catalyst was composed of auxotroph thymine-

1178 EWING ET AL.

dependent Escherichia coli encapsulated in permeable alginate gel, and  $2^1$ -deoxyuridine, was the glycosyl donor. Such conditions were found to glycosylate the aminoimidazole ester (3) to give an isomeric mixture of two nucleosides (53% base conversion) containing 34%  $B-N^1$ (1f) and 66%  $B-N^3$ (6b) which were separated by HPLC [6% acetonitrile in 0.05M triethylammonium hydrogen carbonate pH7.5 (200 x 4 separon SG x 6 $\mu$ )]. In contrast no reaction was observed with other azoles studied, namely, AICA, 4-cyano-5-hydroxyimidazole and 3-amino-4-ethoxycarbonylpyrazole. The ambiguity observed in the site of deoxyribosylation, by this biotransformation method, is contrary to results obtained with pyrimidines and purines, so far studied, in which substitution takes place at sites  $N^1$  and  $N^2$  respectively.

#### References

- G. Mackenzie, G. Shaw and S.E. Thomas, J.C.S. Chem. Comm., 1976, 454.
- 2. J.A. Montgomery and H.J. Thomas, J.Med.Chem. 1972, 15, 182.
- L.B. Townsend in 'Synthetic Procedures in Nucleic Acid Chemistry', Vol.II, Eds. W.N. Zorbach and R.S. Tipson, Wiley-Interscience 1973. R.J. Rousseau, R.K. Robins and L.B. Townsend, J.Het.Chem., 1970, 7, 367.
- 4. G. Mackenzie and G. Shaw, J.C.S. Chem. Comm., 1978, 882.
- C.C. Bhat in 'Synthetic Procedures in Nucleic Acid Chemistry' Vol.I, Eds. W.W. Zorbach and R.S. Tipson, Wiley-Interscience 1968.
- 6. A.C. Bratton and E.K. Marshall, J.Biol, Chem., 1939, 128 537.
- 7. A. Holy and I. Votruba, Nucleic Acids Research, Symposium Series, 1987,  $\underline{18}$ , 69.